30 results about "Cancer relapse" patented technology

The invention relates to correlation between long noncoding RNA (ribonucleic acid) H19 and drug resistance of cancers to platinum chemotherapeutics and relates to usages of medicaments, which are capable of reducing and/or inhibiting expression of the long noncoding RNA H19 in cancer cells, in preparation of medicines for treatment or prevention of cancers and medicines for reducing drug resistance of the cancers to the platinum chemotherapeutics. The invention further relates to usages of medicaments, which are capable of detecting expression of the long noncoding RNA H19, in preparation of detection kits, wherein the detection kits are used for diagnosis of carcinogenesis or predication of cancer relapse and used for predication, detection or diagnosis of drug resistance of cancer patients to the platinum chemotherapeutics. The invention further relates to pharmaceutical compositions comprising the medicaments. The cancers refer to cancers which can be treated with the platinum chemotherapeutics, and preferably, the cancers refer to ovarian cancers.

The invention provides an application of the ACTL6A gene to preparation of a medicine for treating liver cancer or preventing relapse of liver cancer after surgery. Experiments show that when corresponding protein coded by the ACTL6A gene is highly expressed in a cell nucleus, the postoperative cancer relapse rate is increased. Through various known dosage methods, the expression of the corresponding protein coded by the ACTL6A gene is restrained. Thus, the EMT function of liver cancer cells in the human body is effectively prevented, the transferring possibility of liver cancer cells in the human body is reduced, survival time of a patient is prolonged after surgery, and transferring and relapse are reduced.

Provided is an a combination therapy including a radiosensitizing agent and radiation, and being effective to inhibit proliferation of cancer stem cells. Further provided is a combination which includes a radiosensitizing agent and radiation, and effectively reduces incidence of at least one of cancer relapse and metastatic cancer in a subject having a cancer, wherein the cancer includes cancer stem cells. Also provided are anthraquinone derivatives for use as radiosensitizing agents in combination with radiations, the combination therapy being cancer specific. Further, the radiosensitizing agents were found to be cancer specific, namely, some being more effective against a cancer type as compared to others.

The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sensitizing treatment resistant cancer cells or patients with treatment-refractory cancer cells to continuing or starting anti-hormone treatment. Further provided in the invention are methods for prognosis or diagnosis of anti-hormone treatment effect or likelihood of cancer relapse or metastasis following anti-hormone treatment.

The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting tight-junction protein and preventing and treating a cancer relapse and transfer of the postoperative breast cancer. The brand new sequence of the polypeptide is LNLSSTLASGKDATGSYPTLMV. The polypeptide can inhibit proliferation and migration of breast cancer cells in an in-vitro mode, the survival rate of tumor-bearing mice is increased in an in-vivo test, and the polypeptide has the potential new medicine development value.

The invention discloses a traditional Chinese medicine capable of tonifying qi and blood. The traditional Chinese medicine is composed of the following components in parts by weight: 5 to 10 parts of ginseng, 5 to 10 parts of pilos antler, 10 to 20 parts of wolfberry, and 10 to 20 parts of red sage root. The pharmaceutical effect and health care effect of the traditional Chinese medicine are fully exerted. The traditional Chinese medicine can enhance the human immunity, and can also reduce blood sugar, blood fat, and blood pressure, prevent cancer, cancer cell spread, and cancer relapse, improve myocardial blood supply, resist arteriosclerosis, enhance immunity, and delay cell aging.

The invention relates to a preparation method and application of a medicine for preventing cancer relapse, the medicine is mainly suitable for the conditions that after cancer radiotherapy/chemotherapy, a patient is recovered, but the cancer patient suffers from environment change, body change, disease relapse after radiotherapy/chemotherapy and the like, the medicine is mainly prepared from Chinese herbal medicines as main materials and vitamin AD and an inhibitor as auxiliary materials, and the medicine is free of toxic and side effects. The invention relates to main traditional Chinese medicines including coix seeds, Chinese dates, platycodon grandiflorum, cassia twigs, motherwort, poria cocos, charred triplet and vitamin AD. The traditional Chinese medicines are decocted, dried and compressed, different auxiliary medicines are added at the same time, uniform mixing is performed again, and dry powder is formed. The traditional Chinese medicine composition can be taken in the chemoradiotherapy process and can also be independently taken after chemoradiotherapy rehabilitation.

The invention belongs to the technical field of biomedicine, and particularly relates to application of AAV9-CPEB3 in preparation of a medicine for treating gastric cancer. Experiments show that when expression of corresponding protein coded by the CPEB3 gene is reduced in cytoplasm, the postoperative cancer recurrence probability of a patient is increased. Through various known administration modes, expression up-regulation of corresponding protein coded by the CPEB3 gene is realized, so proliferation of gastric cancer cells in a human body after an operation is effectively prevented, the metastasis opportunity of the gastric cancer cells in the human body is reduced, the survival quality of a patient after the operation is thus improved, postoperative rehabilitation is improved, and gastric cancer relapse is prevented.

Methods and compositions which provide a gene expression-based prognostic signature of cancer relapse and prediction of metastatic cancer are described, and in particular methods to predict colorectal cancer (CRC) recurrence and chemosensitivity.

The present invention provides methods of treating cancer in a subject, preventing or delaying relapse to a cancer in a subject in remission, prolonging remission from cancer, increasing survival, and decreasing or alleviating cancer symptoms comprising a) administering histamine dihydrochloride and an inhibitor of the Programmed cell Death protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) or b) administering an agent that decreases reactive oxygen species (ROS) optionally, together with a histamine receptor agonist. The present invention also provides methods of predicting the efficacy of a cancer treatment based on a re-distribution of cytotoxic T cells, frequency of NK cells, or other biochemical changes, and related methods of preventing relapse to cancer and for prolonging remission from a cancer. Related kits and compositions are also provided.